49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05262686
(ClinicalTrials.gov)
March 10, 202222/2/2022Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus ErythematosusEfficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus: a Randomised Prospective StudySystemic Lupus ErythematosusDrug: Belimumab;Drug: Interleukin-2Peking University People's HospitalNULLRecruiting18 Years70 YearsAll10Phase 3China
2NCT04397107
(ClinicalTrials.gov)
August 15, 20206/5/2020The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic DiseasesThe Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis)Systemic Lupus ErythematosusDrug: IL-2The First Hospital of Jilin UniversityNULLRecruitingN/A17 YearsAll46N/AChina
3NCT04077684
(ClinicalTrials.gov)
September 10, 20191/9/2019Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled TrialEfficacy and Safety of Low-dose Interleukin-2 in Patients With Systemic Lupus Erythematosus: a Multicenter, Randomised, Placebo-controlled TrialSystemic Lupus ErythematosusDrug: Interleukin-2Peking University People's HospitalNULLRecruiting18 Years75 YearsAll500Phase 2China
4ChiCTR-IPR-16009451
2016-11-012016-10-16The Efficacy and Safety of Low Dose IL-2 Conbined Rapamycin Therapy in Chinese Over-treated Patients with Systemic Lupus ErythematosusThe Efficacy and Safety of Low Dose IL-2 Conbined Rapamycin Therapy in Chinese Over-treated Patients with Systemic Lupus Erythematosus Systemic Lupus ErythematosusIL-2 group:IL-2;IL-2 + Rapamycin group :IL-2 and Rapamycin;non IL-2 or IL-6 antagonist group :Glucocorticoids and DMARDs;the Second Hospital of Shanxi Medical UniversityNULLPending1880BothIL-2 group:20;IL-2 + Rapamycin group :20;non IL-2 or IL-6 antagonist group :20;China
5NCT02932137
(ClinicalTrials.gov)
May 5, 20168/10/2016Anti-infection of Low-does IL-2 in SLEPotential Effect of Anti-infection by Low-dose IL-2 in Treatment of SLESystemic Lupus ErythematosusDrug: Interleukin-2Peking University People's HospitalNULLCompleted18 Years60 YearsAll30N/AChina
6NCT02084238
(ClinicalTrials.gov)
August 20138/3/2014Low-dose IL-2( Interleukin-2) Treatment in SLESafety and Efficiency Study of Low-dose IL-2 Treatment in Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: Interleukin-2Peking University People's HospitalMonash UniversityCompleted18 Years65 YearsAll40N/AChina